A5010781167- Cervical Cancer and HPV Research
- Genital Health and Disease
- Hepatitis B Virus Studies
- Endometrial and Cervical Cancer Treatments
- Colorectal and Anal Carcinomas
- Ovarian cancer diagnosis and treatment
- Maternal and Perinatal Health Interventions
- Reproductive tract infections research
- Immunotherapy and Immune Responses
- Urological Disorders and Treatments
- Pregnancy-related medical research
- Cancer and Skin Lesions
- Animal Virus Infections Studies
- Global Cancer Incidence and Screening
- Cardiac, Anesthesia and Surgical Outcomes
- Medical and Health Sciences Research
- Uterine Myomas and Treatments
- Microbial infections and disease research
- Intestinal and Peritoneal Adhesions
- Molecular Biology Techniques and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Virus-based gene therapy research
- Pelvic floor disorders treatments
- Urinary and Genital Oncology Studies
- Nonmelanoma Skin Cancer Studies
Medical University of Vienna
2016-2025
Comprehensive Cancer Center Vienna
2016-2025
Universitätsklinik für Frauenheilkunde und Geburtshilfe
1994-2023
U-M Rogel Cancer Center
2023
Vienna General Hospital
1996-2022
Royal Women's Hospital
2009-2018
Institut National de Santé Publique du Québec
2010-2018
Murdoch Children's Research Institute
2018
University of Virginia
2018
Royal Children's Hospital
2009-2018
The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in quadrivalent (qHPV) (6, 11, 16, and 18) five additional oncogenic (31, 33, 45, 52, 58). Here we present results of a study efficacy immunogenicity 9vHPV women 16 to 26 years age.
Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated.We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 genotyping performed biopsy samples, histological diagnoses were determined by a pathology panel. Analyses...
The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women they were "negative to 14 HPV types" mixed HPV-exposed -unexposed (intention-to-treat group).This analysis studied 17 622 aged 15-26 years who enrolled one two randomized, placebo-controlled, efficacy trials for HPV6/11/16/18 (first patient December 28, 2001, studies...
The placebo arm of human papillomavirus (HPV) vaccine trials helps define the natural history genital warts (GW).Women enrolled in (n = 8800) 2 randomized a quadrivalent were examined for presence GW up to 9 visits over approximately 4 years. A comprehensive examination perianal area, vulva, and vagina prompted biopsy. Biopsy samples analyzed by blinded panel histopathologists tested 14 HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) use polymerase chain reaction-based...
Objectives To evaluate the prophylactic efficacy of human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias anogenital warts (condyloma acuminata).
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We an update on the efficacy of quadrivalent against high-grade lesions based end-of-study data three clinical trials. Additionally, we stratify by several baseline characteristics, including age, smoking status, Papanicolaou (Pap) test results. A total 18,174 females ages 16 26 years were randomized allocated into one trials...
To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on risk developing subsequent disease after an excisional procedure for cervical intraepithelial neoplasia or diagnosis genital warts, vulvar neoplasia, vaginal neoplasia.
Knowledge of differences in human papillomavirus (HPV)-type prevalence between high-grade cervical intraepithelial neoplasia (HG-CIN) and invasive cancer (ICC) is crucial for understanding the natural history HPV-infected lesions potential impact HPV vaccination on prevention. More than 6,000 women diagnosed with HG-CIN or ICC from 17 European countries were enrolled two parallel cross-sectional studies (108288/108290). Centralised histopathology review standardised HPV-DNA typing applied to...
BackgroundWe evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59) associated with >20% cancers. The population included HPV-naive women preexisting and/or HPV-related at enrollment MethodsPhase 3 efficacy studies enrolled 17,622 aged 16–26 years. Subjects underwent cervicovaginal sampling Pap testing day 1 then 6–12-month intervals for up 4 typing was performed...
ObjectiveIn the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program, 73% of women aged 16-26 were naïve to all types. In these women, prophylactic administration was highly effective in preventing 6/11/16/18-related cervical disease. Of remaining 15% had evidence past infection with one or more types (seropositive and DNA negative) at time enrollment. Here we present an analysis this group determine efficacy 6/11/16/18 against new external anogenital disease...
Abstract Background: We estimated the prevalence and incidence of 14 human papillomavirus (HPV) types (6/11/16/18/31/33/35/39/45/51/52/56/58/59) in cervicovaginal swabs, attribution these HPV cervical intraepithelial neoplasia (CIN), adenocarcinoma situ (AIS), using predefined algorithms that adjusted for multiple-type infected lesions. Methods: A total 10,656 women ages 15 to 26 years 1,858 24 45 were enrolled placebo arms one three clinical trials a quadrivalent vaccine. cumulative...
We evaluated the overall agreement between colposcopically directed biopsies and definitive excisional specimens within context of three clinical trials. A total 737 women aged 16-45 who had a cervical biopsy taken 6 months before their therapy were included. Per-protocol, colposcopists to also obtain representative immediately therapy. Using adjudicated histological diagnoses, initial same day correlated with surgically excised specimens. The therapy, diagnoses was 42% (weighted kappa =...
Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence type-distribution CGN vary, providing uncertain evidence support prophylactic vaccination HPV screening. This study [108288/108290] assessed women diagnosed adenocarcinoma situ (AIS, N = 49), adenosquamous carcinoma (ASC, 104), various...
ObjectiveNine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and cervical surgeries related to all nine components was assessed compared with a historic placebo population. This not in the 9vHPV trial since quadrivalent HPV (qHPV) vaccine-controlled, measured for five types covered only by (HPV31/33/45/52/58), but four both vaccines (HPV6/11/16/18).MethodsThree international, randomized, double-blind studies were conducted using same methodology. In study (NCT00543543),...
The European Society of Gynaecological Oncology (ESGO), the International for Study Vulvovaginal Disease (ISSVD), College Vulval (ECSVD), and Federation Colposcopy (EFC) developed consensus statements on pre-invasive vulvar lesions in order to improve quality care patients with squamous intraepithelial neoplasia, Paget disease situ, melanoma situ. For differentiated neoplasia (dVIN), an excisional procedure must always be adopted. high-grade lesion (VHSIL), both procedures ablative ones can...